Reduced Fas ligand-expressing splenic CD5 + B lymphocytes in severe collagen-induced arthritis

Arthritis Research and Therapy

Volumn 11, Issue 4, 2009, Pages

  Lundy, Steven K ^a   Fox, David A ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD5 ANTIGEN; FAS LIGAND; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; LYMPHOCYTE ANTIGEN RECEPTOR;

ANIMAL; APOPTOSIS; ARTHRITIS; ARTICLE; B LYMPHOCYTE; BIOSYNTHESIS; COCULTURE; CYTOLOGY; FLOW CYTOMETRY; GENETICS; HELPER CELL; IMMUNOLOGY; METABOLISM; MOUSE; RHEUMATOID ARTHRITIS; SPLEEN; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; ANTIGENS, CD5; APOPTOSIS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTE SUBSETS; B-LYMPHOCYTES; COCULTURE TECHNIQUES; FAS LIGAND PROTEIN; FLOW CYTOMETRY; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-17; MICE; RECEPTORS, ANTIGEN, T-CELL; SPLEEN; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 73349120279     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2795     Document Type: Article

References (51)

1. Klareskog L, Padyukov L, Ronnelid J, Alfredsson L. Genes, environment and immunity in the development of rheumatoid arthritis. Curr Opin Immunol 2006, 18:650-655. 10.1016/j.coi.2006.06.004, 17010589.
2. Lundy SK, Sarkar S, Tesmer LA, Fox DA. Cells of the synovium in rheumatoid arthritis. T lymphocytes. Arthritis Res Ther 2007, 9:202-212. 10.1186/ar2107, 1860060, 17306038.
3. Nepom GT. Structural and genetic features of human leukocytic antigen class II elements associated with rheumatoid arthritis. Am J Med 1988, 85:12-13. 10.1016/0002-9343(88)90372-5, 2462345.
4. Goronzy JJ, Weyand CM. Interplay of T lymphocytes and HLA-DR molecules in rheumatoid arthritis. Curr Opin Rheumatol 1993, 5:169-177. 10.1097/00002281-199305020-00008, 8452767.
5. Albani S, Roudier J. Molecular basis for the association between HLA DR4 and rheumatoid arthritis. From the shared epitope hypothesis to a peptidic model of rheumatoid arthritis. Clin Biochem 1992, 25:209-212. 10.1016/0009-9120(92)90328-P, 1378777.
6. Lubberts E, Koenders MI, Berg WB. The role of T-cell interleukin-17 in conducting destructive arthritis: lessons from animal models. Arthritis Res Ther 2005, 7:29-37. 10.1186/ar1478, 1064899, 15642151.
7. Lubberts E, Joosten LA, Loo FA, Schwarzenberger P, Kolls J, Berg WB. Overexpression of IL-17 in the knee joint of collagen type II immunized mice promotes collagen arthritis and aggravates joint destruction. Inflamm Res 2002, 51:102-104. 10.1007/BF02684010, 11930902.
8. Nakae S, Nambu A, Sudo K, Iwakura Y. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol 2003, 171:6173-6177.
9. Lubberts E, Koenders MI, Oppers-Walgreen B, Bersselaar L, Coenen-de Roo CJ, Joosten LA, Berg WB. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum 2004, 50:650-659. 10.1002/art.20001, 14872510.
10. Chabaud M, Garnero P, Dayer JM, Guerne PA, Fossiez F, Miossec P. Contribution of interleukin 17 to synovium matrix destruction in rheumatoid arthritis. Cytokine 2000, 12:1092-1099. 10.1006/cyto.2000.0681, 10880256.
11. Kuligowska M, Odrowaz-Sypniewska G. Role of interleukin-17 in cartilage and bone destruction in rheumatoid arthritis. Ortop Traumatol Rehabil 2004, 6:235-241.
12. Tesmer LA, Lundy SK, Sarkar S, Fox DA. Th17 cells in human disease. Immunol Rev 2008, 223:87-113. 10.1111/j.1600-065X.2008.00628.x, 18613831.
13. Weaver CT, Harrington LE, Mangan PR, Gavrieli M, Murphy KM. Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity 2006, 24:677-688. 10.1016/j.immuni.2006.06.002, 16782025.
14. Harrington LE, Mangan PR, Weaver CT. Expanding the effector CD4 T-cell repertoire: the Th17 lineage. Curr Opin Immunol 2006, 18:349-356. 10.1016/j.coi.2006.03.017, 16616472.
15. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, Weaver CT. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005, 6:1123-1132. 10.1038/ni1254, 16200070.
16. Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, Wang Y, Hood L, Zhu Z, Tian Q, Dong C. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005, 6:1133-1141. 10.1038/ni1261, 1618871, 16200068.
17. Nagata S. Fas ligand-induced apoptosis. Annu Rev Genet 1999, 33:29-55. 10.1146/annurev.genet.33.1.29, 10690403.
18. Suda T, Nagata S. Why do defects in the Fas-Fas ligand system cause autoimmunity?. J Allergy Clin Immunol 1997, 100:S97-101. 10.1016/S0091-6749(97)70013-7, 9440553.
19. Kim SH, Kim S, Oligino TJ, Robbins PD. Effective treatment of established mouse collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express FasL. Mol Ther 2002, 6:584-590. 10.1016/S1525-0016(02)90712-4, 12409256.
20. Nagafuchi H, Wakisaka S, Takeba Y, Takeno M, Sakane T, Suzuki N. Aberrant expression of Fas ligand on anti-DNA autoantibody secreting B lymphocytes in patients with systemic lupus erythematosus: 'immune privilege'-like state of the autoreactive B cells. Clin Exp Rheumatol 2002, 20:625-631.
21. Bonardelle D, Benihoud K, Kiger N, Bobe P. B lymphocytes mediate Fas-dependent cytotoxicity in MRL/lpr mice. J Leukoc Biol 2005, 78:1052-1059. 10.1189/jlb.0904536, 16204618.
22. Lundy SK. Killer B lymphocytes: the evidence and the potential. Inflamm Res 2009, 10.1007/s00011-009-0014-x, 19262989.
23. Lundy SK, Boros DL. Fas ligand-expressing B-1a lymphocytes mediate CD4(+)-T-cell apoptosis during schistosomal infection: induction by interleukin 4 (IL-4) and IL-10. Infect Immun 2002, 70:812-819. 10.1128/IAI.70.2.812-819.2002, 127725, 11796615.
24. O'Garra A, Howard M. IL-10 production by CD5 B cells. Ann N Y Acad Sci 1992, 651:182-199. 10.1111/j.1749-6632.1992.tb24615.x, 1376039.
25. Amel Kashipaz MR, Huggins ML, Lanyon P, Robins A, Powell RJ, Todd I. Assessment of Be1 and Be2 cells in systemic lupus erythematosus indicates elevated interleukin-10 producing CD5+ B cells. Lupus 2003, 12:356-363. 10.1191/0961203303lu338oa, 12765298.
26. Brand DD, Myers LK, Whittington KB, Latham KA, Stuart JM, Kang AH, Rosloniec EF. Detection of early changes in autoimmune T cell phenotype and function following intravenous administration of type II collagen in a TCR-transgenic model. J Immunol 2002, 168:490-498.
27. Tsark EC, Wang W, Teng YC, Arkfeld D, Dodge GR, Kovats S. Differential MHC class II-mediated presentation of rheumatoid arthritis autoantigens by human dendritic cells and macrophages. J Immunol 2002, 169:6625-6633.
28. Tran CN, Davis MJ, Tesmer LA, Endres JL, Motyl CD, Smuda C, Somers EC, Chung KC, Urquhart AG, Lundy SK, Kovats S, Fox DA. Presentation of arthritogenic peptide to antigen-specific T cells by fibroblast-like synoviocytes. Arthritis Rheum 2007, 56:1497-1506. 10.1002/art.22573, 17469112.
29. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods 1995, 184:39-51. 10.1016/0022-1759(95)00072-I, 7622868.
30. Chu CQ, Swart D, Alcorn D, Tocker J, Elkon KB. Interferon-gamma regulates susceptibility to collagen-induced arthritis through suppression of interleukin-17. Arthritis Rheum 2007, 56:1145-1151. 10.1002/art.22453, 17393396.
31. Burastero SE, Casali P. Characterization of human CD5 (Leu-1, OKT1)+ B lymphocytes and the antibodies they produce. Contrib Microbiol Immunol 1989, 11:231-262.
32. Smith HR, Olson RR. CD5+ B lymphocytes in systemic lupus erythematosus and rheumatoid arthritis. J Rheumatol 1990, 17:833-835.
33. Pers JO, Jamin C, Predine-Hug F, Lydyard P, Youinou P. The role of CD5-expressing B cells in health and disease (review). Int J Mol Med 1999, 3:239-245.
34. Burastero SE, Cutolo M, Dessi V, Celada F. Monoreactive and polyreactive rheumatoid factors produced by in vitro Epstein-Barr virus-transformed peripheral blood and synovial B lymphocytes from rheumatoid arthritis patients. Scand J Immunol 1990, 32:347-357. 10.1111/j.1365-3083.1990.tb02929.x, 1700467.
35. Kipps TJ, Vaughan JH. Genetic influence on the levels of circulating CD5 B lymphocytes. J Immunol 1987, 139:1060-1064.
36. Sowden JA, Roberts-Thomson PJ, Zola H. Evaluation of CD5-positive B cells in blood and synovial fluid of patients with rheumatic diseases. Rheumatol Int 1987, 7:255-259. 10.1007/BF00270525, 3326144.
37. Youinou P, Mackenzie L, Katsikis P, Merdrignac G, Isenberg DA, Tuaillon N, Lamour A, Le Goff P, Jouquan J, Drogou A, Muller S, Genetet B, Moutsopoulos HM, Lydyard PM. The relationship between CD5-expressing B lymphocytes and serologic abnormalities in rheumatoid arthritis patients and their relatives. Arthritis Rheum 1990, 33:339-348. 10.1002/art.1780330306, 1690541.
38. Jones BM, Cheng IK, Wong RW, Kung AW. CD5-positive and CD5-negative rheumatoid factor-secreting B cells in IgA nephropathy, rheumatoid arthritis and Graves' disease. Scand J Immunol 1993, 38:575-580. 10.1111/j.1365-3083.1993.tb03244.x, 7504827.
39. Markeljevic J, Batinic D, Uzarevic B, Bozikov J, Cikes N, Babic-Naglic D, Horvat Z, Marusic M. Peripheral blood CD5+ B cell subset in the remission phase of systemic connective tissue diseases. J Rheumatol 1994, 21:2225-2230.
40. Hassan J, Yanni G, Hegarty V, Feighery C, Bresnihan B, Whelan A. Increased numbers of CD5+ B cells and T cell receptor (TCR) gamma delta+ T cells are associated with younger age of onset in rheumatoid arthritis (RA). Clin Exp Immunol 1996, 103:353-356. 2200359, 8608631.
41. Evans JG, Chavez-Rueda KA, Eddaoudi A, Meyer-Bahlburg A, Rawlings DJ, Ehrenstein MR, Mauri C. Novel suppressive function of transitional 2 B cells in experimental arthritis. J Immunol 2007, 178:7868-7878.
42. Mauri C, Ehrenstein MR. The 'short' history of regulatory B cells. Trends Immunol 2008, 29:34-40. 10.1016/j.it.2007.10.004, 18289504.
43. Fillatreau S, Gray D, Anderton SM. Not always the bad guys: B cells as regulators of autoimmune pathology. Nat Rev Immunol 2008, 8:391-397. 10.1038/nri2315, 18437156.
44. Lund FE, Garvy BA, Randall TD, Harris DP. Regulatory roles for cytokine-producing B cells in infection and autoimmune disease. Curr Dir Autoimmun 2005, 8:25-54. full_text, 15564716.
45. Hata H, Sakaguchi N, Yoshitomi H, Iwakura Y, Sekikawa K, Azuma Y, Kanai C, Moriizumi E, Nomura T, Nakamura T, Sakaguchi S. Distinct contribution of IL-6, TNF-alpha, IL-1, and IL-10 to T cell-mediated spontaneous autoimmune arthritis in mice. J Clin Invest 2004, 114:582-588. 503774, 15314695.
46. Spencer NF, Daynes RA. IL-12 directly stimulates expression of IL-10 by CD5+ B cells and IL-6 by both CD5+ and CD5- B cells: possible involvement in age-associated cytokine dysregulation. Int Immunol 1997, 9:745-754. 10.1093/intimm/9.5.745, 9184920.
47. Tinhofer I, Marschitz I, Kos M, Henn T, Egle A, Villunger A, Greil R. Differential sensitivity of CD4+ and CD8+ T lymphocytes to the killing efficacy of Fas (Apo-1/CD95) ligand+ tumor cells in B chronic lymphocytic leukemia. Blood 1998, 91:4273-4281.
48. Leandro MJ, Edwards JC, Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis 2002, 61:883-888. 10.1136/ard.61.10.883, 1753912, 12228157.
49. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004, 350:2572-2581. 10.1056/NEJMoa032534, 15201414.
50. Hamaguchi Y, Uchida J, Cain DW, Venturi GM, Poe JC, Haas KM, Tedder TF. The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice. J Immunol 2005, 174:4389-4399.
51. Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 2006, 54:613-620. 10.1002/art.21617, 16447239.